Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
Trial Profile

An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Mitazalimab (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms OPTIMIZE-1
  • Sponsors Alligator Bioscience

Most Recent Events

  • 20 Jan 2026 According to an Alligator Biosciences media release, data from the trial will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA, taking place 8-11 January 2026.
  • 05 Nov 2025 According to an Alligator Biosciences media release, data from the trial will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held 5-9 November 2025 in National Harbor, MD, USA.
  • 23 Oct 2025 According to an Alligator Biosciences media release, 24-month data from the trial were presented at ESMO GI..

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top